
## David K Shay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2212287/publications.pdf Version: 2024-02-01



Πλυίρ Κ Shav

#	Article	IF	CITATIONS
1	Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. JAMA - Journal of the American Medical Association, 2003, 289, 179.	3.8	3,197
2	Influenza-Associated Hospitalizations in the United States. JAMA - Journal of the American Medical Association, 2004, 292, 1333.	3.8	1,892
3	Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996. JAMA - Journal of the American Medical Association, 1999, 282, 1440.	3.8	1,199
4	Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infectious Diseases, The, 2012, 12, 687-695.	4.6	1,047
5	Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young Children. New England Journal of Medicine, 2000, 342, 232-239.	13.9	956
6	Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States. JAMA - Journal of the American Medical Association, 2006, 295, 891.	3.8	591
7	Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommendations and Reports, 2010, 59, 1-62.	26.7	589
8	Influenza-Associated Deaths among Children in the United States, 2003–2004. New England Journal of Medicine, 2005, 353, 2559-2567.	13.9	564
9	Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults. New England Journal of Medicine, 2003, 348, 1747-1755.	13.9	561
10	Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008. Clinical Infectious Diseases, 2012, 54, 1427-1436.	2.9	475
11	Bronchiolitisâ€Associated Mortality and Estimates of Respiratory Syncytial Virus–Associated Deaths among US Children, 1979–1997. Journal of Infectious Diseases, 2001, 183, 16-22.	1.9	441
12	The Burden of Communityâ€Acquired Pneumonia in Seniors: Results of a Populationâ€Based Study. Clinical Infectious Diseases, 2004, 39, 1642-1650.	2.9	394
13	Trends in Hospitalizations for Pneumonia Among Persons Aged 65 Years or Older in the United States, 1988-2002. JAMA - Journal of the American Medical Association, 2005, 294, 2712.	3.8	374
14	Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 2011, 60, 1-24.	26.7	340
15	Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recommendations and Reports, 2008, 57, 1-60.	26.7	318
16	Influenza-Associated Pediatric Mortality in the United States: Increase of <i>Staphylococcus aureus</i> Coinfection. Pediatrics, 2008, 122, 805-811.	1.0	313
17	Estimates of US influenzaâ€associated deaths made using four different methods. Influenza and Other Respiratory Viruses, 2009, 3, 37-49.	1.5	307
18	Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clinical Infectious Diseases, 2014, 58, 319-327.	2.9	303

#	Article	IF	CITATIONS
19	Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season. Journal of Infectious Diseases, 2009, 199, 159-167.	1.9	288
20	Mask use, hand hygiene, and seasonal influenza-like illness among young adults: A randomized intervention trial. Journal of Infectious Diseases, 2010, 201, 491-498.	1.9	265
21	Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommendations and Reports, 2009, 58, 1-52.	26.7	256
22	Incidence of Outpatient Visits and Hospitalizations Related to Influenza in Infants and Young Children. Pediatrics, 2004, 113, 585-593.	1.0	249
23	Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years. New England Journal of Medicine, 2007, 357, 1281-1292.	13.9	246
24	The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine, 2013, 31, 3104-3109.	1.7	233
25	Epidemiology of Seasonal Influenza: Use of Surveillance Data and Statistical Models to Estimate the Burden of Disease. Journal of Infectious Diseases, 2006, 194, S82-S91.	1.9	231
26	Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains. Clinical Infectious Diseases, 2012, 55, 951-959.	2.9	227
27	Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology, 2007, 36, 623-631.	0.9	226
28	Influenza- and RSV-associated hospitalizations among adults. Vaccine, 2007, 25, 846-855.	1.7	206
29	Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 2006, 55, 1-42.	26.7	178
30	Effectiveness of Influenza Vaccine during Pregnancy in Preventing Hospitalizations and Outpatient Visits for Respiratory Illness in Pregnant Women and Their Infants. American Journal of Perinatology, 2004, 21, 333-339.	0.6	175
31	Influenza Vaccine Effectiveness in the Community and the Household. Clinical Infectious Diseases, 2013, 56, 1363-1369.	2.9	174
32	Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011. PLoS ONE, 2013, 8, e66312.	1.1	173
33	Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccineâ€Naive 5–8‥earâ€Old Children. Journal of Infectious Diseases, 2006, 194, 1032-1039.	1.9	169
34	Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infectious Diseases, The, 2015, 15, 293-300.	4.6	166
35	Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recommendations and Reports, 2007, 56, 1-54.	26.7	165
36	Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatric Infectious Disease Journal, 2003, 22, 483-489.	1.1	164

#	Article	IF	CITATIONS
37	Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism. Pediatrics, 2010, 126, 656-664.	1.0	155
38	Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine, 2009, 27, 6546-6549.	1.7	154
39	Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 680-684.	9.0	152
40	Innate Immune Function and Mortality in Critically Ill Children With Influenza. Critical Care Medicine, 2013, 41, 224-236.	0.4	149
41	Bronchiolitis Management Preferences and the Influence of Pulse Oximetry and Respiratory Rate on the Decision to Admit. Pediatrics, 2003, 111, e45-e51.	1.0	148
42	Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatric Infectious Disease Journal, 2001, 20, 646-653.	1.1	140
43	Active Surveillance of Vaccine Safety. Epidemiology, 2005, 16, 336-341.	1.2	137
44	Effectiveness of Seasonal Trivalent Influenza Vaccine for Preventing Influenza Virus Illness Among Pregnant Women: A Population-Based Case-Control Study During the 2010–2011 and 2011–2012 Influenza Seasons. Clinical Infectious Diseases, 2014, 58, 449-457.	2.9	134
45	Clinical Characteristics and 30-Day Outcomes for Influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) Infections. JAMA - Journal of the American Medical Association, 2010, 304, 1091.	3.8	133
46	Multistate Surveillance for Laboratory-Confirmed, Influenza-Associated Hospitalizations in Children. Pediatric Infectious Disease Journal, 2006, 25, 395-400.	1.1	126
47	Monitoring Influenza Activity in the United States: A Comparison of Traditional Surveillance Systems with Google Flu Trends. PLoS ONE, 2011, 6, e18687.	1.1	126
48	Influenza-associated mortality in temperate and subtropical Chinese cities, 2003–2008. Bulletin of the World Health Organization, 2012, 90, 279-288B.	1.5	125
49	Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old. JAMA - Journal of the American Medical Association, 2006, 296, 1990.	3.8	121
50	Unraveling <i>R</i> <sub>0</sub> : Considerations for Public Health Applications. American Journal of Public Health, 2014, 104, e32-e41.	1.5	121
51	Estimating Influenza-Associated Deaths in the United States. American Journal of Public Health, 2009, 99, S225-S230.	1.5	120
52	Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatric Infectious Disease Journal, 2000, 19, 11-17.	1.1	113
53	Impact of Maternal Influenza Vaccination During Pregnancy on the Incidence of Acute Respiratory Illness Visits Among Infants. JAMA Pediatrics, 2006, 160, 1277.	3.6	104
54	Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities. PLoS ONE, 2011, 6, e23085.	1.1	103

#	Article	IF	CITATIONS
55	Perinatal Risk Factors for Infant Hospitalization With Viral Gastroenteritis. Pediatrics, 1999, 103, e3-e3.	1.0	102
56	Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 2007, 25, 4029-4037.	1.7	99
57	Influenza Circulation and the Burden of Invasive Pneumococcal Pneumonia during a Nonâ€pandemic Period in the United States. Clinical Infectious Diseases, 2010, 50, 175-183.	2.9	95
58	Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012–2013 and 2013–2014. Journal of Infectious Diseases, 2017, 215, 510-517.	1.9	93
59	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021. Annals of Internal Medicine, 2022, 175, 513-522.	2.0	93
60	Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza and Other Respiratory Viruses, 2012, 6, 37-43.	1.5	91
61	Bloodstream infections in home infusion patients: The influence of race and needleless intravascular access devices. Journal of Pediatrics, 1996, 129, 711-717.	0.9	87
62	Mortality from Pneumonia in Children in the United States, 1939 through 1996. New England Journal of Medicine, 2000, 342, 1399-1407.	13.9	85
63	Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021. Morbidity and Mortality Weekly Report, 2022, 71, 90-95.	9.0	82
64	Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results. Vaccine, 2011, 29, 6558-6563.	1.7	81
65	Effectiveness of Interventions to Reduce Contact Rates during a Simulated Influenza Pandemic. Emerging Infectious Diseases, 2007, 13, 581-589.	2.0	78
66	Studies Needed to Address Public Health Challenges of the 2009 H1N1 Influenza Pandemic: Insights from Modeling. PLoS Medicine, 2010, 7, e1000275.	3.9	75
67	Household Responses to School Closure Resulting from Outbreak of Influenza B, North Carolina. Emerging Infectious Diseases, 2008, 14, 1024-30.	2.0	73
68	The Burden of Influenza-Associated Critical Illness Hospitalizations*. Critical Care Medicine, 2014, 42, 2325-2332.	0.4	70
69	Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. Vaccine, 2015, 33, 3003-3009.	1.7	69
70	Development and Estimation of a Pediatric Chronic Disease Score Using Automated Pharmacy Data. Medical Care, 1999, 37, 874-883.	1.1	68
71	Comparison of Nasal and Nasopharyngeal Swabs for Influenza Detection in Adults. Clinical Medicine and Research, 2012, 10, 215-218.	0.4	58
72	Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. , 2012, 3, 68-90.		58

#	Article	IF	CITATIONS
73	Outpatient and Hospital Visits Associated With Otitis Media Among American Indian and Alaska Native Children Younger Than 5 Years. Pediatrics, 2002, 109, e41-e41.	1.0	57
74	Unraveling <i>R</i> <sub>0</sub> : Considerations for Public Health Applications. American Journal of Public Health, 2018, 108, S445-S454.	1.5	56
75	Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination. Annals of Internal Medicine, 2003, 139, 1.	2.0	53
76	An Outbreak of Acute Gastroenteritis in a Geriatric Long-Term–Care Facility: Combined Application of Epidemiological and Molecular Diagnostic Methods. Infection Control and Hospital Epidemiology, 1999, 20, 306-311.	1.0	48
77	A Large, Population-Based Study of 2009 Pandemic Influenza A Virus Subtype H1N1 Infection Diagnosis During Pregnancy and Outcomes for Mothers and Neonates. Journal of Infectious Diseases, 2012, 206, 1260-1268.	1.9	45
78	Epidemiology of Pandemic Influenza: Use of Surveillance and Modeling for Pandemic Preparedness. Journal of Infectious Diseases, 2006, 194, S92-S97.	1.9	43
79	Asthma and Bronchiolitis Hospitalizations Among American Indian Children. JAMA Pediatrics, 2000, 154, 991.	3.6	41
80	Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. Vaccine, 2013, 31, 2057-2061.	1.7	39
81	Regional variation in mortality impact of the 2009 <scp>A</scp> ( <scp>H</scp> 1 <scp>N</scp> 1) influenza pandemic in <scp>C</scp> hina. Influenza and Other Respiratory Viruses, 2013, 7, 1350-1360.	1.5	39
82	Influenza-Related Hospitalization and ED Visits in Children Less Than 5 Years: 2000–2011. Pediatrics, 2015, 135, e66-e74.	1.0	39
83	Population-based Incidence Estimates of Influenza-associated Respiratory Failure Hospitalizations, 2003 to 2009. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 710-715.	2.5	38
84	Effectiveness of Inactivated Influenza Vaccines in Preventing Influenza-Associated Deaths and Hospitalizations among Ontario Residents Aged ≥65 Years: Estimates with Generalized Linear Models Accounting for Healthy Vaccinee Effects. PLoS ONE, 2013, 8, e76318.	1.1	38
85	The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine, 2012, 30, 3557-3565.	1.7	37
86	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. American Journal of Epidemiology, 2013, 178, 1327-1336.	1.6	37
87	Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infectious Diseases, 2015, 2, ofv052.	0.4	37
88	Influenza and Malaria Coinfection Among Young Children in Western Kenya, 2009–2011. Journal of Infectious Diseases, 2012, 206, 1674-1684.	1.9	35
89	Effect of the 2009 Influenza A(H1N1) Pandemic on Invasive Pneumococcal Pneumonia. Journal of Infectious Diseases, 2013, 207, 1135-1143.	1.9	35
90	Case-Control Study of Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Hospitalizations in Older Adults, United States, 2010–2011. Clinical Infectious Diseases, 2016, 63, 1304-1311.	2.9	33

#	Article	IF	CITATIONS
91	Magnitude of Potential Biases in a Simulated Case-Control Study of the Effectiveness of Influenza Vaccination. Clinical Infectious Diseases, 2012, 54, 25-32.	2.9	32
92	Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 2005, 23, 3697-3703.	1.7	28
93	A Pilot Study of Host Genetic Variants Associated with Influenza-associated Deaths among Children and Young Adults1. Emerging Infectious Diseases, 2011, 17, 2294-2302.	2.0	27
94	Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Review of Vaccines, 2011, 10, 1529-1537.	2.0	27
95	Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine, 2006, 24, 151-156.	1.7	24
96	Effectiveness of 1 Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing Reverse-Transcription Polymerase Chain Reaction-Confirmed H1N1 Infection Among School-Aged Children in Maine. Journal of Infectious Diseases, 2012, 206, 1059-1068.	1.9	24
97	Evaluation of obesity as an independent risk factor for medically attended laboratory onfirmed influenza. Influenza and Other Respiratory Viruses, 2013, 7, 160-167.	1.5	24
98	Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010–2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010–2011 Influenza Season. Journal of Infectious Diseases, 2013, 207, 1262-1269.	1.9	24
99	Influenza Pneumonia Surveillance among Hospitalized Adults May Underestimate the Burden of Severe Influenza Disease. PLoS ONE, 2014, 9, e113903.	1.1	22
100	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 483-489.	1.1	21
101	Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine, 2011, 29, 387-390.	1.7	21
102	The Pregnancy and Influenza Project: design of an observational case-cohort study to evaluate influenza burden and vaccine effectiveness among pregnant women and their infants. American Journal of Obstetrics and Gynecology, 2011, 204, S69-S76.	0.7	21
103	Commentary. Epidemiology, 2012, 23, 839-842.	1.2	19
104	Effects of immunizing school children with 2009 influenza A (H1N1) monovalent vaccine on absenteeism among students and teachers in Maine. Vaccine, 2012, 30, 4835-4841.	1.7	19
105	Inactivated Influenza Vaccines for Prevention of Community-Acquired Pneumonia. Epidemiology, 2013, 24, 530-537.	1.2	19
106	High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses. Vaccine, 2016, 34, 4594-4601.	1.7	19
107	Estimating ageâ€specific influenzaâ€related hospitalization rates during the pandemic (H1N1) 2009 in Davidson Co, TN. Influenza and Other Respiratory Viruses, 2012, 6, e63-71.	1.5	18
108	Incidence of influenzaâ€associated mortality and hospitalizations in Argentina during 2002–2009. Influenza and Other Respiratory Viruses, 2013, 7, 710-717.	1.5	18

#	Article	IF	CITATIONS
109	Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010. Pharmacoepidemiology and Drug Safety, 2013, 22, 335-344.	0.9	17
110	Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50–80 years of age. Human Vaccines and Immunotherapeutics, 2014, 10, 1195-1203.	1.4	17
111	Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza and Other Respiratory Viruses, 2009, 3, 29-35.	1.5	16
112	Demographic, socio-economic and geographic determinants of seasonal influenza vaccine uptake in rural western Kenya, 2011. Vaccine, 2014, 32, 6699-6704.	1.7	15
113	Statin Use and Risks of Influenza-Related Outcomes Among Older Adults Receiving Standard-Dose or High-Dose Influenza Vaccines Through Medicare During 2010–2015. Clinical Infectious Diseases, 2018, 67, 378-387.	2.9	15
114	Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051. Emerging Infectious Diseases, 2008, 14, 1280-1283.	2.0	14
115	Diagnostic performance of the BinaxNow Influenza A&B rapid antigen test in ED patients. American Journal of Emergency Medicine, 2012, 30, 1955-1961.	0.7	14
116	Trends in mortality from respiratory disease in Latin America since 1998 and the impact of the 2009 influenza pandemic. Bulletin of the World Health Organization, 2013, 91, 525-532.	1.5	14
117	Household economic impact and attitudes toward school closures in two cities in Argentina during the 2009 influenza A (H1N1) pandemic. Influenza and Other Respiratory Viruses, 2013, 7, 1308-1315.	1.5	14
118	Child, Household, and Caregiver Characteristics Associated with Hospitalization for Influenza Among Children 6–59 Months of Age. Pediatric Infectious Disease Journal, 2014, 33, e141-e150.	1.1	14
119	Influenza vaccine for community-acquired pneumonia. Lancet, The, 2008, 372, 352-354.	6.3	13
120	Influenza vaccination status is not associated with influenza testing among children: Implications for observational studies of vaccine effectiveness. Vaccine, 2011, 29, 1935-1940.	1.7	13
121	Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000–2010. Influenza and Other Respiratory Viruses, 2012, 6, e143-51.	1.5	13
122	Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study. Nutrition Research, 2014, 34, 149-154.	1.3	13
123	Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells. Oncotarget, 2016, 7, 35512-35521.	0.8	12
124	Adamantane-Resistant Influenza Infection During the 2004–05 Season. Emerging Infectious Diseases, 2008, 14, 173-176.	2.0	11
125	Emergency Department Visits for Influenza A(H1N1)pdm09, Davidson County, Tennessee, USA. Emerging Infectious Diseases, 2012, 18, 863-865.	2.0	11
126	Subjective social status predicts wintertime febrile acute respiratory illness among women healthcare personnel Health Psychology, 2014, 33, 282-291.	1.3	11

#	Article	IF	CITATIONS
127	Effectiveness of Nonadjuvanted Monovalent Influenza A(H1N1)pdm09 Vaccines for Preventing Reverse Transcription Polymerase Chain Reaction–Confirmed Pandemic Influenza Hospitalizations: Case-Control Study of Children and Adults at 10 US Influenza Surveillance Network Sites. Clinical Infectious Diseases, 2013, 57, 1587-1592.	2.9	10
128	El número reproductivo básico ( <i>R</i> <sub>0</sub> ): consideraciones para su aplicación en la salud póblica. American Journal of Public Health, 2018, 108, S455-S465.	1.5	10
129	Can We "Hedge―against the Development of Antiviral Resistance among Pandemic Influenza Viruses?. PLoS Medicine, 2009, 6, e1000103.	3.9	9
130	Estimated rates of influenzaâ€associated outpatient visits during 2001â€2010 in 6 <scp>US</scp> integrated healthcare delivery organizations. Influenza and Other Respiratory Viruses, 2018, 12, 122-131.	1.5	9
131	Influenza vaccination for elderly people and their care workers. Lancet, The, 2006, 368, 1752-1753.	6.3	8
132	A National Survey of the Infectious Diseases Society of America Emerging Infections Network concerning Neuraminidase Inhibitor Prescription Practices and Pandemic Influenza Preparations. Clinical Infectious Diseases, 2006, 43, 494-497.	2.9	8
133	Patterns of seasonal influenza activity in U.S. core-based statistical areas, described using prescriptions of oseltamivir in Medicare claims data. Epidemics, 2019, 26, 23-31.	1.5	8
134	Evaluating oseltamivir prescriptions in Centers for Medicare and Medicaid Services medical claims records as an indicator of seasonal influenza in the United States. Influenza and Other Respiratory Viruses, 2018, 12, 465-474.	1.5	6
135	Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults. Influenza and Other Respiratory Viruses, 2022, 16, 562-567.	1.5	6
136	Validation of a Screening Instrument to Identify Persons for Exclusion from Smallpox Vaccination. Clinical Infectious Diseases, 2005, 40, 620-623.	2.9	5
137	Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose. BMC Pediatrics, 2006, 6, 31.	0.7	5
138	Estimates of the impact of a future influenza pandemic in China. Influenza and Other Respiratory Viruses, 2009, 3, 223-231.	1.5	5
139	Age-Specific Influenza-Related Emergency Department Visits and Hospitalizations in 2010–2011 Compared With the Pandemic Year 2009–2010. Infectious Diseases in Clinical Practice, 2014, 22, 271-278.	0.1	4
140	Schoolâ€Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program. Health Services Research, 2017, 52, 2307-2330.	1.0	4
141	Multiple vaccinations and the risk of medically attended fever. Vaccine, 2010, 28, 4169-4174.	1.7	3
142	Can the rolling cross-sectional survey design be used to estimate the effectiveness of influenza vaccines?. Vaccine, 2014, 32, 6440-6444.	1.7	3
143	Age-specific estimates of US influenza-associated deaths and hospitalizations. International Congress Series, 2004, 1263, 316-320.	0.2	2
144	Shift Shown in Influenza A Adamantane Resistance—Reply. JAMA - Journal of the American Medical Association, 2006, 296, 1585.	3.8	1

#	Article	IF	CITATIONS
145	Comment and Update on Influenza Prevention and Treatment. Clinical Infectious Diseases, 2007, 45, 670-671.	2.9	1
146	Reply to Fedson. Journal of Infectious Diseases, 2014, 209, 1301-1302.	1.9	1
147	Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians. Journal of General Internal Medicine, 2021, 36, 2030-2038.	1.3	1
148	Hospitalization Trends for Pneumonia Among Older Persons—Reply. JAMA - Journal of the American Medical Association, 2006, 295, 2137.	3.8	0